MDACC Study No:2014-0152 ( NCT No: NCT02071927)
Title:A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a single agent and in Combination with Standard Therapy in Patients with Relapsed/ Refractory and/or newly diagnosed Leukemia and/or IDH-Mutated Myelodysplastic Syndrome
Principal Investigator:Marina Konopleva
Treatment Agent:Azacitidine; CB-839
Study Status:Open
Study Description:The goal of Part I of this clinical research study is to find the highest
tolerable dose of CB-839 either alone or in combination with azacitidine that
can be given to patients with newly diagnosed, relapsed, or refractory AML,
ALL, or MDS.

The goal of Part II of this study is to learn if the dose found in Part 1 of
the study can help to control the disease.

The safety of the study drug will be studied in both parts of this study.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:Azacitidine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Calithera Biosciences
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Marina Konopleva
For Clinical Trial Enrollment:713-794-1628
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults